Kaiser Permanente’s Department of Research and Evaluation in Southern California is 1 of 42 health systems selected to participate in a PCORI initiative.
Clinical trials play vital role in advancing cancer treatment at Kaiser Permanente
“Until the day that cancer is cured, there’s always room for improvement,” said hematologist-oncologist Helen Moon, MD.
Striving to achieve that improvement is Dr. Moon’s role as a cancer clinical trials investigator for Kaiser Permanente in Southern California. “Clinical trials assess the standard of care versus the new drugs that are coming down the pipeline,” she explained. “We [evaluate] the newest drugs and improve our patients’ survival.”
One of the most promising new approaches to cancer treatment is immunotherapy, which helps a patient’s immune system fight cancer.
“What we are trying to do conceptually is to mount an immune response against that cancer, so not only does the primary cancer shrink, but you’re left with a memory of that cancer immunologically, and it can guard you against further incidents,” said Dr. Moon. “Immunotherapy has really changed the world for a number of cancer patients.”
Helen Moon, MD, is a clinical trials investigator and oncologist-hematologist from the Southern California Permanente Medical Group, practicing at Kaiser Permanente Riverside Medical Center. This is reprinted from the AboutKP site.